Form 6-K ARGENX SE For: Dec 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Guggenheim on argenx SE (ARGX): 'Long-term Growth Thesis Intact'
December 15, 2025 10:25 AM ESTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $1,085.00 price target on argenx SE (NASDAQ: ARGX).
The analyst comments "We caught up with ARGX following today's announcement regarding the discontinuation of efgartigimod's (anti-FcRn) thyroid eye disease (TED) pivotal study due to futility, which we view as reflective of the specific indication biology with minimal read-across to the Graves'... More
